Abstract

The clinical core of the RADP is a mechanism for prospective enrollment of patients with clinical criteria for probable Alzheimer's disease for post-mortem donation of brain samples; prospective enrollment of normal controls for post-mortem brain samples; assessing retrospectively the clinical histories of demented subjects whose brains are donated post-mortem for research study and making the diagnosis of dementia of the Alzheimer type; and assessing retrospectively the clinical histories of nondemented subjects whose brains are obtained as normal controls.
The aim i s to accrue a total of approximately 75 brains of patients with clinical and pathologic criteria for Alzheimer's disease, and approximately 45 brains from control subjects without clinical or pathologic criteria of any dementia disorder comparable in age and sex to the patients.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG003644-05
Application #
3813774
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1989
Total Cost
Indirect Cost

  Institution

Name
University of Rochester
Department
Type
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627

  Publications

Slemmon, J R; Wengenack, T M; Flood, D G (1997) Profiling of endogenous peptides as a tool for studying development and neurological disease. Biopolymers 43:157-70
Kazee, A M; Cox, C; Richfield, E K (1995) Substantia nigra lesions in Alzheimer disease and normal aging. Alzheimer Dis Assoc Disord 9:61-7
Maguire-Zeiss, K A; Li, Z W; Shimoda, L M et al. (1995) Calbindin D28k mRNA in hippocampus, superior temporal gyrus and cerebellum: comparison between control and Alzheimer disease subjects. Brain Res Mol Brain Res 30:362-6
Wetzel, D M; Bohn, M C; Kazee, A M et al. (1995) Glucocorticoid receptor mRNA in Alzheimer's diseased hippocampus. Brain Res 679:72-81
Flood, D G (1994) Thoughts on no neocortical neuronal loss but loss of volume in AD. Neurobiol Aging 15:363-5;discussion 379-80
Slemmon, J R; Hughes, C M; Campbell, G A et al. (1994) Increased levels of hemoglobin-derived and other peptides in Alzheimer's disease cerebellum. J Neurosci 14:2225-35
Wetzel, D M; Bohn, M C; Hamill, R W (1994) Postmortem stability of mRNA for glucocorticoid and mineralocorticoid receptor in rodent brain. Brain Res 649:117-21
Jette, N; Cole, M S; Fahnestock, M (1994) NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients. Brain Res Mol Brain Res 25:242-50
Benesch, C G; McDaniel, K D; Cox, C et al. (1993) End-stage Alzheimer's disease. Glasgow Coma Scale and the neurologic examination. Arch Neurol 50:1309-15
Kazee, A M; Eskin, T A; Lapham, L W et al. (1993) Clinicopathologic correlates in Alzheimer disease: assessment of clinical and pathologic diagnostic criteria. Alzheimer Dis Assoc Disord 7:152-64

Showing the most recent 10 out of 38 publications